| CAS ID: | 196808-45-4 |
| Molecular Formula: | C34H30N2O5 |
| Molecular Weight: | 546.6 g/mol |
| Monoisotopic Mass: | 546.2155 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | GI262570X | GI262570 | Farglitazar |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C34H30N2O5/c1-23-29(36-33(41-23)26-12-6-3-7-13-26)20-21-40-27-18-16-24(17-19-27)22-31(34(38)39)35-30-15-9-8-14-28(30)32(37)25-10-4-2-5-11-25/h2-19,31,35H,20-22H2,1H3,(H,38,39)/t31-/m0/s1 | See All |
| InChI Key: | ZZCHHVUQYRMYLW-HKBQPEDESA-N | |
| Smiles: | Cc1oc(nc1CCOc2ccc(C[C@H](Nc3ccccc3C(=O)c4ccccc4)C(=O)O)cc2)c5ccccc5 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT00244751 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | October 27, 2005 | Last Verified | December 11, 2017 |
| Sponsor | GlaxoSmithKline | ||
| PubChem: | 170364 |
| ChEMBL: | CHEMBL107367 |